22UA:ETR
BioNTech SE - ADR
€79,80
arrow_downward
-1,60%(-1,30) 1D
14 Okt., 17:35:45 GMT+2 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for 22UA...
Open
€80,25
High
€81,25
Low
€79,70
Mkt. cap
22,27 mjd
Avg. vol.
24,78 k
Volume
25,88 k
52-wk high
€105,70
52-wk low
€68,30
No. of employees
8 k
Open
€80,25
High
€81,25
Low
€79,70
Mkt. cap
22,27 mjd
Avg. vol.
24,78 k
Volume
25,88 k
52-wk high
€105,70
52-wk low
€68,30
No. of employees
8 k
News stories
From web sources and news partners
Pluang
·
1 uur gelede
BioNTech shares drop 7.13% after trial failure raises concerns over oncology program claims
Simply Wall Street
·
15 uur gelede
BioNTech Stock Faces Questions After Cancer Trial Missed Progression Free Survival Goal
TradingKey
·
1 dag gelede
Biontech SE Stock (BNTX) Closed Down by 7.13% on Oct 13: Drivers Behind the Movement
GuruFocus
·
1 dag gelede
BioNTech (BNTX) Shares Slide After BNT113 Vaccine Misses Progres
Profile
BioNTech SE is a German multinational biotechnology company headquartered in Mainz that develops immunotherapies and vaccines, particularly for cancer and infectious diseases.
The company utilizes technology platforms including mRNA-based therapies, targeted therapies, and immunomodulators, to develop its treatments. BioNTech's pipeline includes several late-stage programs in oncology testing combination therapy approaches to improve treatment outcomes.
In the field of infectious diseases, BioNTech, partnering with Pfizer, developed Comirnaty, the first approved mRNA-based vaccine, which was widely used during the COVID-19 pandemic. Wikipedia
About BioNTech SE - ADR